Meloxicam tablet    (DrugBank: Meloxicam)

2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
46悪性関節リウマチ2
271強直性脊椎炎1

46. 悪性関節リウマチ [臨床試験数:4,183,薬物数:2,538(DrugBank:401),標的遺伝子数:183,標的パスウェイ数:219
Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
2 / 4,183 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR1900027855
2019-11-292019-11-30Pharmacokinetics of CYP2C9 * 3 homozygous mutant subjects in a single oral meloxicam tabletPharmacokinetics of CYP2C9 * 3 homozygous mutant subjects in a single oral meloxicam tablet Osteoarthritis, rheumatoid arthritisCase:Meloxicam 15mg;Center for Clinical Pharmacology, the Third Xiangya Hospital, Central South UniversityNULLPending1845MaleCase:1;Phase 1China
2NCT00239382
(ClinicalTrials.gov)
July 1, 200413/10/2005A Study to Compare Meloxicam IM Once Daily Versus Meloxicam Orally Once Daily in Patients With Rheumatoid ArthritisA Randomized, Open-labelled Study to Compare the Efficacy and Safety of Meloxicam 15 mg IM Ampoules Once Daily and Meloxicam 15 mg Tablets Administered Orally Once Daily Over a Period of 7 Days in Patients With RA.Arthritis, RheumatoidDrug: Meloxicam ampoule;Drug: Meloxicam tabletBoehringer IngelheimNULLCompleted18 YearsN/AAll150Phase 3China

271. 強直性脊椎炎 [臨床試験数:531,薬物数:343(DrugBank:66),標的遺伝子数:41,標的パスウェイ数:141
Searched query = "Ankylosing spondylitis", "Spondylarthritis ankylopoietica"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 531 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02183168
(ClinicalTrials.gov)
July 20014/7/2014Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing SpondylitisA Randomized, Open Label, 3-arm Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing SpondylitisSpondylitis, AnkylosingDrug: Meloxicam suppository;Drug: Meloxicam tablet;Drug: IndomethacinBoehringer IngelheimNULLCompletedN/AN/ABoth192Phase 3NULL